For several years, the story of Canada’s licensed producers read more like a survival show than a growth chart. Companies closed facilities, cut staff and restructured their operations. That picture is starting to change. Canadian cannabis producers are reporting stronger margins and steadier profits. However, the businesses coming out of the shakeout look very different from the ones that raced to build capacity after legalisation.

Profit takes over from market share

Auxly chief executive Hugo Alves says the biggest shift was a sharper focus on consumers, markets, products and assets. Most notably, the company stopped treating market share as the ultimate goal. Instead, Alves says his team watches gross margin dollars and cash flow as the key measures of success. As a result, new products only reach shelves when they clear internal profitability thresholds.

Growth still matters to Canadian cannabis producers, but not at any cost. Auxly found that more than 80% of the Canadian market sat in dried flower, pre rolls and vape products. So it put its capital into those three formats and stopped funding the rest. Today, Alves says Back Forty is the country’s biggest cannabis seller by dollars, and it gets there with a lean range of about 100 SKUs.

Demand leads and capacity follows

Cannara Biotech stayed profitable through much of the turmoil that hit other Canadian cannabis producers. Chief operating officer Niko Sosiak says the company built its business around sustainable unit economics rather than growth for growth’s sake. Cannara adds capacity only after it sees real consumer demand, and it concentrates its investment on the Tribal, Nugz and Orchid CBD brands.

The company also controls genetics, cultivation, processing and manufacturing. In addition, its owned facilities and Quebec’s relatively competitive energy costs give it what Sosiak calls a “structural cost advantage”. He says the lesson goes beyond cutting costs.

“Capacity alone does not create a successful cannabis company,” he said. “Consumer demand has to lead production, every product needs a clear role, and capital must be allocated with an expectation of measurable returns.”

Cronos Group chief executive Mike Gorenstein points to the same discipline. He says recent success has come from careful capital allocation and targeted investments, including the expansion of GrowCo. A steady push on research and product development has helped. Canadian cannabis companies that spend with purpose are the ones reporting results.

Owning the supply chain pays off

That emphasis on deliberate spending challenged an assumption from the difficult years. Many believed that owning fewer production assets was the safer path. Auxly went the other way. While many producers chased models that kept few assets, the company took full ownership of its Leamington cultivation facility. Alves says controlling its own flower supply was critical to building strong products and brands.

“Our thesis was correct,” he said. He describes the purpose built hybrid greenhouse as able to produce high quality cannabis consistently and “at a very competitive cost.” The lesson, then, is less about whether Canadian cannabis producers should own assets. Rather, it is about whether those assets have a clear purpose tied to demand and sustainable returns.

Winning at home or abroad

Canadian cannabis companies no longer agree on where the next stage of growth will come from. For Auxly, the priority stays domestic.

“Our strategy is to win at home, and we believe that if you can’t win at home, there is little reason to believe that you can win internationally over the longer term,” Alves said. He adds that the Canadian market “can be highly profitable with a focused strategy”.

Alves also sees room for the home market to keep growing. Legal operators could capture more sales from the illicit market, he says, and cannabis is becoming more socially accepted. New products could help cannabis take a greater share of consumer spending from alcohol and tobacco. That ambition says a great deal about where the industry wants to go.

Cronos takes a different view among Canadian cannabis producers. International markets sit at the centre of its business model.

“Cronos has always been a global business, and the breadth of our international footprint continues to provide meaningful growth as we execute our borderless products strategy,” Gorenstein said.

The company entered Israel in 2017 and has invested more than 100 million New Israeli Shekels in a greenhouse, a manufacturing facility and an R&D lab. Gorenstein says Peace Naturals is now the country’s number one medical cannabis brand. Cronos also operates in Germany and other international markets.

A maturing industry or survival of the fittest

Sosiak sees the changes as something bigger than the success of a few Canadian cannabis producers. Asked whether stronger results show a maturing industry or simply the strongest operators surviving a long correction, he answered, “It is a combination of both.” Consumers know more, he says, while retailers and provincial boards focus more on product consistency and velocity. Producers have also tightened their grip on capacity, pricing, inventory and capital.

The shakeout has reshaped the field.

“A prolonged shakeout has concentrated demand and shelf space among operators with relevant brands, efficient cost structures, and the financial capacity to continue investing,” said Sosiak.

Alves accepts that Auxly has benefited from a shrinking number of viable competitors. He expects more change soon, given the number of insolvencies announced this year. Gorenstein sees the results as proof of lessons learned. In Canada, he points to the Spinach brand, including its position in the edible and vape categories, as evidence that the strategy works.

Even so, the structural challenges have not vanished. Sosiak lists excise taxes, regulatory costs and intense price competition as continuing pressures. He warns against declaring an industry wide turnaround from a few strong quarters.

“The real test will be whether those results translate into consistent profitability and operating cash flow over multiple quarters,” he said.

This period stands apart from earlier waves of optimism. Bigger companies, larger facilities and growing market share are no longer enough on their own. For the wider public, the question now is what a sharper, more profitable industry will do with its new focus. Canadian cannabis producers have learned to read demand closely, and plenty of people outside the sector will be watching how they use that skill.

Source: stratcann